AACR 2022 poster. Using solid tumor analytical validation of T-regulatory immunohistochemistry multiplex for clinical studies

Our Histoprofile®- T-reg light panel is ready for use in your clinical trials

Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.

 

Amanda Finan

The Complexity of Myeloid-Derived Suppressor Cells in Non-small Cell Lung Cancer: A Combinatorial Multiplex IHC and Flow Cytometry Approach

In Situ Multiplex Analysis of Regulatory and Effector T Cells in Multiple Tumor Types

In Situ Multiplex Analysis of Resident Microglia and Infiltrating Macrophages in Glioblastoma

Multiplex Immunofluorescence Detection of Resident Memory T Cells in Solid Tumors

Assessing Clinical Response in Multiple Myeloma Patients Treated with Monoclonal Antibodies

Immune Cell Checkpoint Profiling of Solid Tumors

Immune checkpoint proteins are important regulators in self-tolerance but also allow cancer cells to evade immune destruction. Checkpoint inhibitor (CKI) blockade therapies can help restore antitumoral immunity. Combination blockade has demonstrated the potential to result in greater tumor growth inhibition than monotherapies in preclinical studies. Multiplex immunofluorescence offers a technical advantage by allowing for the detection of co-expression and spatial organization of multiple targets within a preserved tissue architecture on a single slide. We have developed the HISTOPROFILE®-CKI multiplex immunohistochemistry panel to offer personalized immune cell checkpoint profiling.

Aramchol, Scd1 Inhibitor, Improves Liver Glucose Homeostasis In NASH

Metabolomic Characterization Of Very Early Hepatocellular Carcinoma In Cirrhotic Patients Submitted For Liver Transplantation

Non-Invasive Serum Lipidomic Approach To Discriminate Non-Alcoholic Steatohepatitis In Multiethnic Patients With Type 2 Diabetes Mellitus